Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting

NCT02012569 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Burns
Traumatic Lesions

Interventions

DRUG: TT-173
DRUG: Placebo

Sponsor

Thrombotargets Europe S.L